

Results for Dasatinib and Quercetin Senolytic Therapy Risk-Benefit Analysis

|  |                   | <a href="#">New Articles</a>   | False Negatives   | <a href="#">False Positives</a> |                                |
|--|-------------------|--|---|---------------------------------|--------------------------------|
| Table 2: Estimated Relevance for False Negatives until 17. April, 2020 included in the Risk-Benefit Analysis but not classified as relevant. |                   |  |   |                                 |                                |
| Relevance  | Date              | Title  | Abstract  | Expand                          | URL                            |
| 0.3  | 22. März, 2013    | Bioavailability of quercetin: problems and promises  | Quercetin (QC) is a typical plant flavonoid, possesses d... | <div>+</div>                    | <a href="#">pubmed</a>         |
| 0.29   | 1. Januar, 2005   | Cytotoxicity of flavonoids toward cultured normal hum...   | The cytotoxicity of flavonoids, including apigenin, erio... | <div>+</div>                    | <a href="#">pubmed</a>         |
| 0.25   | 6. Februar, 2016  | Association Between BCR-ABL Tyrosine Kinase Inhib...   | Importance: A phase 3 trial with ponatinib in patients ...  | <div>+</div>                    | <a href="#">pubmed</a>         |
| 0.24   | 22. August, 2016  | <b>Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial (IPF)</b><br><b>Abstract</b><br>The study team hypothesizes that intermittent (3 doses administered over 3 consecutive days in 3 consecutive weeks) oral administration of combination Dasatinib (100 mg/d) + Quercetin (1250 mg/d) will be safe and well tolerated in patients with IPF. Treatment with D+Q will result in reduced abundance of pro-inflammatory cells within subjects over baseline. Finally, the reduction in biomarkers of cellular pro-inflammatory state will be related to no change in functional and patient reported outcomes. |   | <div>-</div>                    | <a href="#">clinicaltrials</a> |
| 0.22   | 19. Januar, 2017  | Identification of cellular targets involved in cardiac fail...   | Aims: The aims of the present study were to evaluate t...   | <div>+</div>                    | <a href="#">pubmed</a>         |
| 0.22   | 3. Oktober, 2017  | Short-term High Dose of Quercetin and Resveratrol Alt...   | Background: Hyperglycemia-mediated oxidative stress ...     | <div>+</div>                    | <a href="#">pubmed</a>         |
| 0.22   | 14. Februar, 2018 | BCR-ABL Tyrosine Kinase Inhibitors: Which Mechani...   | Imatinib, the first-in-class BCR-ABL tyrosine kinase in...  | <div>+</div>                    | <a href="#">pubmed</a>         |
| 0.19   | 1. Januar, 2008   | Quercetin pharmacokinetics in humans   | The purpose of this study was to examine the pharmac...     | <div>+</div>                    | <a href="#">pubmed</a>         |
| 0.18   | 6. Mai, 2009      | Tyrosine kinase inhibitor-induced platelet dysfunction i...  | Dasatinib is associated with increased risk of bleeding ... | <div>+</div>                    | <a href="#">pubmed</a>         |
| 0.18   | 17. März, 2004    | Quercetin, an over-the-counter supplement, causes neur...  | A 22-month-old boy, who regularly consumed the oral ...     | <div>+</div>                    | <a href="#">pubmed</a>         |
| Page: <a href="#">1</a> 2  |                   |  |   |                                 |                                |